John Seymour
MBBS, PhD
Director, Lymphoma Service; Professor of Medicine
👥Biography 个人简介
John Seymour is an Australian lymphoma investigator who contributed to the landmark GALLIUM trial demonstrating superiority of obinutuzumab over rituximab in combination with chemotherapy for frontline follicular lymphoma. His research encompasses the biology of type I versus type II anti-CD20 antibodies and mechanisms of superior activity of obinutuzumab. He has led multiple pivotal lymphoma trials through Australian cooperative groups and international partnerships. He is a respected voice in global lymphoma guideline development.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 John Seymour 的研究动态
Follow John Seymour's research updates
留下邮箱，当我们发布与 John Seymour（Peter MacCallum Cancer Centre）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment